AlgoNomics developed a sound structural bioinformatics platform over the past 20 years:

• Tripole® was developed to enhance the characterization and optimization of therapeutic peptides, antibodies and proteins
• Epibase® allows accurate T-cell epitope prediction for profiling and Immunoprofiling® of therapeutic antibodies and proteins, and the design of prophylactic and therapeutic vaccines.

Advantages using our AlgoNomics' technology platforms

AlgoNomics Tripole® and Epibase® based services offer you:

• accurate and cost-effictive in silico T-cell epitope profiling of therapeutic peptides and proteins, and subsequent services implying deimmunization, humanization, epitope enhancement, thereby optimizing the lead prior to going to the lab.
• build additional IP on peptide and epitope leads.
• predict and improve binding possibilities on drug targets that are hard to find in a laboratory environment. Based on the Tripole® platform, escape mutations of proteins or viruses can be predicted, and peptide lead characteristics can be improved by optimized library tuning.
• a better understanding of protein and peptide molecular structures and binding properties.
• acceleration and cost reduction of the lead discovery and optimization, by completing in silico screening and design prior to committing resources in the laboratory

Both technology platforms are powered by our proprietary algorithm FASTER.

Epibase epitope discovery is applied to therapeutic proteins and vaccine development.